Therapeutic drug monitoring for peripartum use of imipenem/cilastatin

Wei LIU,Li-qin ZHU,Xian-hu ZHANG,Yuan WEI,Xin XIONG,Yang LIU,Li YANG
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2015.13.025
2015-01-01
Abstract:Objective To report a case of peripartum use of imipenem/cilastatin supported by therapeutic drug monitoring ( TDM ) technique. Methods A 29-week pregnant woman was prescribed imipenem/cilas-tatin because of intrauterine infection , to ensure the safety of this Food and Drug Administration ( FDA ) Class C drug , pharmacists carried out TDM for this patient.Results and Conclusion By establishing a rapid analyzing method , the parent venous blood and fetus umbilical cord blood was measured.The concentration of imipenem/cilastatin were within nor-mal range in both the mother and the baby .Through follow-up, no ad-verse event were developed and both were discharged later .By providing TDM and pharmaceutical care , the pharmacists supported the clinical us-age of peripartum anti -infectious therapy , and more experience and con-fidence would be gained and shared .
What problem does this paper attempt to address?